Clinical trials recruiting at the time of writing of this manuscript
| Product . | Identifier . | Cell therapy . | n . |
|---|---|---|---|
| MSC | NCT02359929 | Autologous BM-derived MSC for the treatment of acute and chronic GVHD | 24 |
| NCT02032446 | Umbilical cord derived MSC in combination with pentostatin for steroid-refractory acute GVHD | 47 | |
| NCT03847844 | Umbilical cord derived MSC for steroid-refractory acute GVHD | 40 | |
| Treg | NCT02423915 | Fucosylated Treg at day −1 pre-HCT to prevent GVHD | 47 |
| NCT01795573 | Donor Treg cells at day −2 pre-HCT to prevent GVHD | 48 | |
| NCT02749084 | Donor Treg to treat refractory chronic GVHD | 20 | |
| NCT02385019 | Donor Treg to treat refractory chronic GVHD | 22 | |
| NCT03683498 | Donor Treg to treat ruxolitinib-refractory chronic GVHD | 16 | |
| NCT01903473 | Donor Treg in combination with rapamycin to treat ruxolitinib-refractory chronic GVHD | 35 |
| Product . | Identifier . | Cell therapy . | n . |
|---|---|---|---|
| MSC | NCT02359929 | Autologous BM-derived MSC for the treatment of acute and chronic GVHD | 24 |
| NCT02032446 | Umbilical cord derived MSC in combination with pentostatin for steroid-refractory acute GVHD | 47 | |
| NCT03847844 | Umbilical cord derived MSC for steroid-refractory acute GVHD | 40 | |
| Treg | NCT02423915 | Fucosylated Treg at day −1 pre-HCT to prevent GVHD | 47 |
| NCT01795573 | Donor Treg cells at day −2 pre-HCT to prevent GVHD | 48 | |
| NCT02749084 | Donor Treg to treat refractory chronic GVHD | 20 | |
| NCT02385019 | Donor Treg to treat refractory chronic GVHD | 22 | |
| NCT03683498 | Donor Treg to treat ruxolitinib-refractory chronic GVHD | 16 | |
| NCT01903473 | Donor Treg in combination with rapamycin to treat ruxolitinib-refractory chronic GVHD | 35 |
Search terms: “graft versus host disease” and “MSC,” “Treg,” “ILC,” “dendritic cells,” “iNKT cells,” MDSC,” “CAR T cells,” and “CHAR T cells.” The latter 6 search terms did not yield any active studies.
BM, bone marrow; n, expected number of patients to be included in the trial.